Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 92%
filed 2026-09-24
The filing discloses the appointment of Timothy Goldsmith as a director and Audit Committee Chair effective September 24, 2026. While the Item 5.02 section also mentions compensatory arrangements and other committee changes, the principal disclosed action is Goldsmith's appointment to the board and his assumption of the Audit Committee Chair role. The press release emphasizes his appointment as the headline event and notes his extensive audit and SEC reporting experience is critical to BOXABL's governance infrastructure as a newly public company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-24
Item 5.02
Tony Weisman was appointed as a Class I director of Ibotta effective September 22, 2026, and assigned to the Audit Committee. Weisman brings 30+ years of CPG marketing leadership and prior board experience at public companies including Klaviyo and MNTN.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-24
Item 5.02
The filing discloses the promotion of Ross Tackett to Chief Revenue Officer effective October 1, 2026, succeeding Mike Rich. While the section also mentions Rich's departure and severance benefits, the principal disclosed action centers on Tackett's appointment to a C-suite officer role. The press release emphasizes his qualifications, experience, and strategic importance to the company's revenue operations and go-to-market execution, making the appointment the salient event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-24
Item 5.02
The filing discloses the appointment of two new directors, James T. Caulfield (former PepsiCo CFO) and Michael J. Skipworth (Wingstop CEO), to Kontoor's Board effective immediately, with board size increased from seven to nine. Both appointees bring significant executive experience and were assigned to key board committees (Audit, Nominating & Governance, and Talent & Compensation), making this a material governance event affecting board composition and oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-24
Item 5.02
The filing discloses the appointment of two directors to Clover Health's Board: Senator Robert G. Torricelli (Class I director, Audit Committee) and Dr. Brian J. Miller (Class III director, Clinical Committee), effective September 22, 2026. These appointments fill two previously disclosed vacancies and bring the Board to nine directors. While the disclosure also mentions compensatory arrangements (pro-rata retainer and $200,000 RSU awards), the principal disclosed action is the appointment of these two individuals to board positions, making exec_appointment the most salient classification.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-24
EX-99.1
The exhibit announces the Board's appointment of Michael Akkerman as Chief Executive Officer, effective November 2, 2026, succeeding founder Or Offer. This is a material executive appointment at the C-suite level. While Or Offer's departure is also disclosed, the principal action disclosed is Akkerman's appointment to the CEO role, making exec_appointment the appropriate classification. The appointment of a new CEO with extensive C-level experience at major technology and data companies is material to investors assessing leadership continuity and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-24
Item 5.02
Paul Beiboer was appointed to Lineage's Board of Directors effective September 23, 2026, and assigned to the Talent and Compensation Committee. James Wyper resigned from the Board on September 22, 2026. Additionally, Sudarsan Thattai transitioned from Chief Transformation Officer to Special Adviser under a transition agreement.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-23
Item 5.02
Scott E. Powell is being appointed to the role of Chief Risk Officer effective January 15, 2027, representing a material executive appointment at a major financial institution. While the disclosure also notes his departure from the Chief Operating Officer role, the principal disclosed action centers on his appointment to a new C-suite position, making exec_appointment the most salient classification.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-23
EX-99.1
The filing discloses the appointment of Javier Maldonado Trinchant as alternate director of Banco Santander-Chile by Board resolution on September 22, 2026, following the resignation of Alfonso Gómez Morales. This is a clear executive/governance appointment event. Although a departure also occurred, the principal disclosed action is the appointment of a new director, making exec_appointment the appropriate classification. Director appointments are material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-23
Item 1.01
Stoneridge entered into an employment agreement with Uwe Brandenburg to serve as Global Vice President, Engineering & Innovation, effective November 2, 2026, reporting directly to the CEO and serving as a member of the Executive Team. While Item 1.01 technically covers "Entry into a Material Definitive Agreement," the substance of this disclosure is the appointment of a senior executive to lead the company's global Engineering organization. The filing emphasizes Brandenburg's extensive experience and strategic importance to the company's technology roadmap, making this a material executive appointment rather than a routine contract disclosure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-09-23
Item 5.02
Michael Steib was appointed as Chief Executive Officer of Angi Inc. effective September 22, 2026, succeeding Jeffrey W. Kip. The appointment includes a comprehensive employment agreement with significant equity incentives (1,000,000 RSUs and 1,000,000 PSUs), and represents a material leadership transition at the company.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-23
EX-99.1
The exhibit announces the appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to the Board of Directors as strategic AI advisor. These are discrete executive and board appointments that would materially affect investor assessment of the company's leadership and strategic direction, particularly given the appointees' prominent backgrounds (Hart from Eli Lilly's genetic medicines team; Wolf as co-founder and CSO of Hugging Face) and their direct relevance to ProQR's stated AI strategy for its Axiomer RNA editing platform.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-23
Item 5.02
Alan M. Sebulsky was appointed to the Board of Directors as a Class I director effective September 23, 2026, bringing 40+ years of healthcare investment and biopharmaceutical portfolio management experience, including prior board service at Jazz Pharmaceuticals and Arrow International.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-23
EX-99.1
The exhibit discloses the results of an Extraordinary General Meeting held on 23 September 2026 at which shareholders passed a resolution to appoint Mr. Mikael Øpstun Skov as a Director of Hafnia Limited. This is a clear executive/board appointment event requiring disclosure under Item 5.02 equivalent governance rules.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-23
Item 5.02
Five Below elected Scott Settersten, former CFO of Ulta Beauty with 15 years at PwC, to its Board of Directors and Audit Committee, effective September 21, 2026. The appointment includes an initial equity grant of 545 restricted stock units and represents a material governance event affecting board composition and financial oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-23
Item 7.01
Justin Gunn was appointed as President of the Endocrinology division, effective October 1, 2026, with a reporting line to the CEO and membership on the Executive Team.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-09-23
The filing discloses the appointment of Mr. Letao Zhao as an independent director and member of three board committees, including chairperson of the Compensation Committee, effective September 18, 2026. While the filing also mentions the resignation of Mr. Mike Yao Zhou on the same date, the principal disclosed action is the appointment of a new director to fill the vacancy. The appointment of an independent director to multiple committees is material to governance and investor assessment.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-23
EX-99.1
The exhibit announces the appointment of Rafael Siqueira as Chief Technology Officer (CTO) of Agi Inc, a named executive officer role. The disclosure emphasizes his 30 years of technology experience and 16+ years as CTO, his mandate to lead the Technology division and accelerate AI strategy, and notes that his appointment as a statutory officer of Banco Agibank is subject to Central Bank of Brazil approval. This is a material executive appointment that would affect investor assessment of the company's technology leadership and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-23
Item 5.02
The disclosure centers on the Board's election of Mark C. Krebs as a director (Class I) of both the Company and the Bank on September 21, 2026, and his appointment to three Board committees. Although Krebs previously served as Treasurer and CFO until his retirement on June 30, 2025, and then as an advisor, the principal action disclosed here is his appointment to the Board—a governance role change material to investors assessing leadership composition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-23
The filing discloses the appointment of Sheng-Yih Chang as Chief Executive Officer and Chairman of the Board effective September 21, 2026, following the resignation of Kewei Huang. While both a departure and appointment occur, the principal disclosed action centers on the appointment of Chang to the top leadership roles. Chang's prior service as CEO (April 2024–September 2026) and CFO (June 2018–April 2024) establishes his continuity and qualifications. This is material to investors as it affects the registrant's leadership structure and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-23
Item 5.02
LaTanya Langley is being appointed to a new executive role as Chief Administrative and Legal Officer and Corporate Secretary, effective October 1, 2026. Although she is departing her prior role as Chief People Officer, the principal disclosed action is the appointment to a more senior position overseeing legal and administrative functions. The appointment of a named executive to a C-suite role is material to investors assessing the company's leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-23
Item 5.02
Sabrina Farmer was appointed to Flywire's Board of Directors as a Class II director effective September 22, 2026, with her term expiring at the 2029 annual meeting. She was assigned to the Nominating and Corporate Governance Committee and will receive initial and annual RSU awards totaling $350,000 and $175,000 respectively.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-23
Item 5.02
The Company's Board approved the appointment of Howard Sudnow as an independent director effective at the Merger Effective Time (expected Q4 2026), with detailed qualifications and compensation terms disclosed. While the filing occurs in the context of a pending merger, the principal disclosed action is the appointment of a new director to the Board, making this an executive appointment event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-23
Item 5.02
Enhanced Group Inc. announced multiple board-level appointments: Michael Sepso as a new director and Audit Committee member (with a $370,000 initial RSU grant), James Simpson as new Chairman of the Board, and Anthony D. Eisenberg as Chair of the Audit Committee. The appointments also coincided with the resignations of two directors, James J. Murren and Christian Angermayer (the former Chairman).
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-23
Item 5.02
Amy Miller was elected as a director representing Wheatland Rural Electric Association on Tri-State's Board of Directors, effective September 22, 2026. This is a director appointment disclosed under Item 5.02, and board composition changes are material to investors assessing governance and oversight.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-23
Diageo announces the appointment of Joanne Wilson as Chief Financial Officer, joining the Board and Executive Committee in 2027, replacing Nik Jhangiani. The announcement includes detailed compensation terms (£900,000 salary, pension, incentive plans, and replacement awards), confirming this is a material executive appointment. The CFO role is a named executive officer position critical to investor assessment of management continuity and financial leadership.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-23
Pearson announces the appointment of three new Non-Executive Directors (Michael Barkin, Vivek Sharma, and Alex Svensson) effective 1 October 2026. This is a governance event involving the appointment of directors to the Board, which is material to investors as it affects board composition and strategic direction. The announcement explicitly identifies these as new Board members joining the Pearson Board of Directors.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-09-23
Item 5.02
Dean Zikria, a current board member, was appointed as Interim Chief Executive Officer of Valion Bio effective September 22, 2026. The appointment also includes compensatory arrangements (monthly fee of $23,333, 50,000 RSUs, and potential bonus) and is accompanied by related board leadership transitions including Thomas Jensen's appointment as Board Chair and Sheryle Bolton's resignation.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-23
Item 5.02
The filing discloses the appointment of Vidhyadhar Mitta to the Board of Directors effective September 21, 2026. Although Mr. Mitta previously served as a director, the principal disclosed action is his appointment/re-appointment to the Board. The filing also references a prior Debt Exchange Agreement from October 2025 in which Mr. Mitta converted debt to preferred stock, but the core event triggering this 8-K Item 5.02 disclosure is the director appointment itself.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-23
Item 5.02
The filing discloses the appointment of Dritan Muneka as the Company's Principal Accounting Officer (PAO) and Corporate Controller, effective September 30, 2026, following Robert Rico's resignation. While both a departure and appointment occur, the principal disclosed action centers on the appointment of a new PAO—a key accounting leadership role—with detailed background information on the appointee's qualifications and experience at KPMG. The appointment of a PAO is material to investors' assessment of the registrant's financial reporting controls and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-22
Item 5.02
The disclosure centers on the appointment of Robert W. Hau as Executive Vice President and Chief Financial Officer effective November 1, 2026, following his recent promotion to Senior Vice President, Finance. While the section also mentions Robert P. Fishman's concurrent resignation from the Interim CFO role, the principal action disclosed is Hau's appointment to a material C-suite position. The detailed compensation package (base salary $775,000, $2.5M equity award, $200K new hire bonus) and executive background underscore the materiality of this appointment to investors.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-22
Item 5.02
The filing discloses the election of Worthing F. Jackman to the Board of Directors effective immediately on September 22, 2026, along with his appointment to two Board committees. While the section also mentions Dr. Kasarda's retirement, the substantive focus and primary action is Jackman's appointment as a director with significant prior executive experience (former CEO of Waste Connections, current board member of Quanta Services and Executive Chair of WillScot Holdings). This is a material governance event affecting board composition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-22
Item 5.02
Benjamin Hart was appointed to Group 1 Automotive's Board of Directors effective November 1, 2026, pursuant to a Stockholder Agreement with Conifer Management, one of the company's largest shareholders. Hart is a member of the investment team for Acacia funds managed by Conifer, and the appointment expands the board from ten to eleven directors.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-22
Item 5.02
The filing's primary disclosure is the appointment of Ravi Srivastava as Chief Financial Officer, effective September 17, 2026. While the section also discloses the departure of Everett W. Good as CFO, the salient event centers on the appointment of Srivastava to the principal financial officer role. The filing provides detailed background on Srivastava's qualifications and tenure, and confirms Melissa Long's appointment as principal accounting officer. This is material as it involves a change in the Company's principal financial officer position.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-22
Item 5.02
Amanda Fabiano was appointed as a Class III director of Cypherpunk Technologies effective September 22, 2026. Fabiano is a veteran mining executive with significant operational experience from Nakamoto, TeraWulf, Galaxy, and Fidelity, and received RSU awards of 250,000 shares as part of her appointment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-22
Item 5.02
The company appointed Scott Young as Executive Vice President and Chief Operating Officer effective September 22, 2026, in a newly created C-suite role unifying business segments and reporting directly to the CEO. The filing also discloses the appointment of Dev Chakraborty as Senior Vice President and Head of Brigit as part of additions to the executive leadership team.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-22
EX-99.1
The press release announces the appointment of Dr. Michael Blough as Chief Clinical Development Officer, a newly created executive position. The appointment is material because Dr. Blough will oversee critical clinical development strategy for two pivotal trials (Phase 2 psilocybin for major depressive disorder and Phase 3 MDMA for PTSD) that are central to the company's regulatory pathway and value creation. His 20+ years of experience in clinical trials and established relationships with Health Canada directly support the company's near-term clinical milestones.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-22
Item 5.02
Steven K. Burke, M.D., was appointed to the Board of Directors effective September 18, 2026, and to the Nominating and Corporate Governance Committee. Dr. Burke brings 30+ years of biopharmaceutical industry experience with specific expertise in drug development for chronic kidney disease, directly relevant to the company's SCY-770 program for ADPKD.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-22
Item 5.02
Ken Toombs was appointed to Vogenx's Board of Directors as a Class II director effective September 21, 2026, with concurrent appointments as Chair of the Audit Committee and member of the Compensation Committee and Nominating and Corporate Governance Committee. This appointment strengthens independent board oversight for the recently IPO'd clinical-stage biopharmaceutical company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-22
Item 5.02
Jamaal T. Lesane's appointment as Executive Vice President and Chief Legal Officer is the principal disclosed action. While the filing also mentions his departure from the COO role and Bryan Warner's loss of executive officer status, the salient event is Lesane's elevation to a C-suite legal position, which is material to investors assessing leadership and governance. The appointment of a Chief Legal Officer is a significant executive change warranting disclosure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 90%
filed 2026-09-22
Item 7.01
Prabha Sipi Bhandari was appointed as Chief Legal Officer and Corporate Secretary, assuming responsibility for all legal and compliance activities globally, while Christopher M. Crain transitioned to Corporate Senior Advisor.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-22
Item 5.02
Kyle Miller was elected President of United Parks & Resorts effective September 22, 2026, following a 31-year tenure with the company and prior service as Chief Parks Operations Officer. The appointment includes detailed compensation arrangements comprising a base salary of $400,000, bonus and long-term incentive targets, and equity grants totaling $2.5 million.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-22
Item 5.02
Wendy L. Schoppert was elected to the Board of Directors of Piper Sandler Companies effective September 22, 2026, increasing the board size from 10 to 11 directors and appointed to the Audit Committee. Her appointment reflects her substantial executive background as CFO of Sleep Number and current directorships at DaVita and Fossil Group.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-22
Item 5.02
Matthew J. Cushing was appointed as a director of ECB Bancorp, Inc. and its subsidiary Everett Co-operative Bank on September 16, 2026, with a term expiring at the 2027 annual meeting. He was also appointed to the Audit Committee. This is a clear executive appointment disclosure under Item 5.02, and director appointments are material to investors as they affect board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-22
Item 8.01
Karen Larson was appointed as an Independent Board Member of CTT Pharmaceutical. The appointment is material as board composition changes affect investor assessment of corporate governance and oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-22
The filing discloses the appointment of Jaime K. Pickett as a director of PetVivo Holdings, Inc., effective September 22, 2026, to fill a vacancy created by Diane Levitan's resignation. While both a departure and appointment occur, the principal disclosed action centers on the appointment of a new director with extensive veterinary healthcare and executive leadership experience. The Board explicitly determined that Dr. Pickett's qualifications in multi-site operations, corporate strategy, and animal-health technology commercialization were material factors in her selection, making this a material governance event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-22
The filing discloses the appointment of Michael K. Handley as a director of PetVivo Holdings, Inc., effective September 22, 2026, to fill a vacancy created by Joseph Jasper's resignation. While both a departure and appointment occur, the principal disclosed action centers on the appointment of a new director with extensive life sciences and capital-raising experience (25+ years, $700M+ raised, $4B+ in transactions). The Board's detailed explanation of Handley's qualifications and the CEO's statement emphasizing his value to the company's growth strategy indicate this is a material governance event affecting board composition and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-22
The filing discloses the conditional appointment of two directors, Jeff M. Pies and Dena Lauren Decker, to fill vacancies created by a Board expansion from four to six directors. Although the appointments are conditional on Nasdaq or NYSE listing approval, the Board has taken affirmative action to appoint these individuals effective upon satisfaction of listing conditions. This is a material governance event affecting board composition and is the principal disclosed action under Item 5.02.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-22
The filing discloses that Yakov Baranes was appointed as sole Chief Executive Officer effective September 22, 2026, following the departure of co-CEO Amihay Hadad. While both a departure and appointment occurred, the principal disclosed action centers on the appointment of Baranes to the CEO role, which is a material executive leadership change. The appointment of a sole CEO following a co-CEO structure represents a significant governance transition material to investors.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-22
Item 5.02
Kevin M. Rayment was appointed President and Chief Executive Officer effective January 1, 2027, and elected to the Board of Directors. While the disclosure also includes compensatory arrangements (base salary of $1,100,000, 125% bonus target, and $5,225,000 long-term incentive award), the principal disclosed action is Rayment's appointment to the CEO role and Board membership. This is a material executive succession event affecting the registrant's leadership structure.
View raw filing on EDGAR →